Sun Pharmaceutical Industries (Sun Pharma) has announced the biggest acquisition in its history, agreeing to buy US-based Organon in an all-cash deal valued at $11.75 billion, including debt.
The transaction is the largest deal ever in Indian pharma and among the biggest overseas takeovers by an Indian company.
Investors gave an immediate thumbs up.
Sun Pharma shares jumped sharply in trade, rising 7.58% to Rs 1,742.80 on the BSE in the latest session.
The company will pay $14 per share for Organon, offering shareholders a premium over the stock’s previous closing price. The deal has been approved by the boards of both companies and is expected to close in early 2027, subject to regulatory and shareholder approvals.
It may be noted that Jefferies LLC and JP Morgan Securities LLC are serving as financial advisors to Sun Pharma on the transaction.
Large acquisitions often worry investors because they usually involve debt, integration risks and uncertainty. But markets appear to believe this is a strategic buy rather than an expensive gamble.
The acquisition gives Sun Pharma immediate scale in key global markets and expands its portfolio beyond its traditional strengths in generics and specialty medicines.
Organon was spun off from Merck & Co. in 2021 and has built businesses in women’s health, biosimilars and established medicines. It operates in around 140 countries, giving Sun Pharma a much wider commercial reach.
For Sun Pharma, the deal strengthens its position in segments expected to see long-term demand growth, particularly women’s health.
Sun Pharma has long been India’s largest drugmaker, with a strong domestic business and growing overseas presence.
But the Organon acquisition signals a sharper move toward becoming a diversified global pharmaceutical company.
The company, like many peers, has been navigating pricing pressure in the US generics market. Expanding into branded products and specialty segments can help improve margins and reduce dependence on commoditised businesses.
The deal will be funded through a mix of internal cash and borrowings, making leverage and post-merger integration key areas of focus for investors.
Markets will watch how smoothly Sun Pharma absorbs Organon’s operations, manages debt, and unlocks growth from the acquired portfolio.
This is more than a routine acquisition.
With its biggest-ever deal, Sun Pharma is signalling that it wants a much larger role in global healthcare markets.
If executed well, the Organon buyout could become a defining moment in the company’s evolution from India’s top pharma company to a broader multinational player.